A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

BACKGROUND: Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound neutropenia following induction and/or consolidation chemotherapy and this may result in serious, potentially life-threatening, infecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sierra, Jorge, Szer, Jeffrey, Kassis, Jeannine, Herrmann, Richard, Lazzarino, Mario, Thomas, Xavier, Noga, Stephen J, Baker, Nigel, Dansey, Roger, Bosi, Alberto
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483721/
https://www.ncbi.nlm.nih.gov/pubmed/18616811
http://dx.doi.org/10.1186/1471-2407-8-195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483721/
https://www.ncbi.nlm.nih.gov/pubmed/18616811
http://dx.doi.org/10.1186/1471-2407-8-195

Ejemplares similares